Home › Compare › RZSMF vs ABBV
RZSMF yields 7.80% · ABBV yields 3.06%● Live data
📍 RZSMF pulled ahead of the other in Year 1
Combined, RZSMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RZSMF + ABBV for your $10,000?
RCS MediaGroup S.p.A. operates as a multimedia publishing company in Italy, Spain, and internationally. The company publishes newspapers under the Corriere della Sera, Corriere Salute, SOLFERINO, Buone Notizie, Dataroom, La Gazzetta dello Sport, El Mundo, Marca, Expansión, L'Economia, La Lettura, ViviMilano, CI-Corriere Innovazione, and Gazzetta Selection names; and magazines in the women, oggi, interior design, men and lifestyle, travel, and other areas under the MARCA MOTOR, Oggi, AMICA, 7, Abitare, Living, Style, TELVA, Io Donna, DOVE, Sportweek, Insieme, Metrópoli, ACTUALIDAD ECONÓMICA, Fuera de Serie, Italian Style, Io e il mio Bambino, SFERA editore, Oggi Cucino, Style Piccoli, Quimamme, Yo Dona, Sano & Leggero, Bimbinfiera, and Oggi Enigmistica names. It also operates MYBEAUTYBOX, corrierstore.it, doveclub.it, quimammeshop.it, gazzettastore.it, dirittierisposte.it, buonpertutti.corriere.it, and magic.gazzetta.it websites; and TV and radio channels under the Dove Lifestyle, Lei, Radio Marca, Caccia e Pesca, and Corriere TV names. In addition, the company offers print and digital advertising solutions under the RCS PUBBLICITA, m-dis, Imagine, CORREO FARMACÉUTICO, DIARIO MÉDICO, and Infanzia names, as well as sells mobile phone top-up services; and organizes sports and other events, such as roadshows, guerrilla events, sampling, trade marketing, and press conferences under the RCS Sport, SALA BUZZATI, and Last Lap names. The company was formerly known as Holding di Partecipazioni Industriali S.p.A. and changed its name to RCS MediaGroup S.p.A. in 2003. RCS MediaGroup S.p.A. is based in Milan, Italy.
Full RZSMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.